In a phase 2 study, patients with chronic hepatitis D virus (HDV) infection were treated with either a combination of tobebibart and elebsiran every 4 weeks or tobebibart alone every 2 weeks. After 24 weeks of treatment, 47% of patients in the combination group and 70% of patients in the tobebibart alone group achieved a combined improvement (low or resolution of HDV RNA and normalization of ALT). A virological response was noted in 100% of patients in the combination group and in 82% in the tobevibart alone group. Normalization of ALT was observed in 47% of patients in the combined group and in 76% in the tobebibart alone group. Both treatment regimens resulted in a decrease in HDV RNA and ALT levels up to week 48. The drug combination was associated with a higher incidence of low or undetectable HDV RNA and a decrease in HBsAg. The study showed that both treatments are effective in treating chronic HDV.